Erratum: Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials (Brain (2011) 134 (3547-3559) DOI: 10.1093/brain/awr291);Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials

Brain

Volumn 134, Issue 12, 2011, Pages 3544-3556

  Anthony, Karen ^a   Cirak, Sebahattin ^a   Torelli, Silvia ^a   Tasca, Giorgio ^b   Feng, Lucy ^a   Arechavala Gomeza, Virginia ^a   Armaroli, Annarita ^c   Guglieri, Michela ^d   Straathof, Chiara S ^e   Verschuuren, Jan J ^e   Aartsma Rus, Annemieke ^e   Helderman Van Den Enden, Paula ^e   Bushby, Katherine ^d   Straub, Volker ^d   Sewry, Caroline ^a   Ferlini, Alessandra ^c   Ricci, Enzo ^f   Morgan, Jennifer E ^a   Muntoni, Francesco ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

Becker muscular dystrophy; Duchenne muscular dystrophy; dystrophin associated glycoprotein complex; nNOS; therapy

Indexed keywords

BETA DYSTROGLYCAN; DYSTROPHIN; NEURONAL NITRIC OXIDE SYNTHASE;

ADOLESCENT; ADULT; AGED; BECKER MUSCULAR DYSTROPHY; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; GENE DELETION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SKELETAL MUSCLE; WESTERN BLOTTING;

EID: 83755220617     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww044     Document Type: Erratum

References (54)

1. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30: 293-9.
2. Abbs S, Tuffery-Giraud S, Bakker E, Ferlini A, Sejersen T, Mueller CR. Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscul Disord 2010; 20: 422-7.
3. Arechavala-Gomeza V, Kinali M, Feng L, Brown SC, Sewry C, Morgan JE, et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol 2010a; 36: 265-74.
4. Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, Main M, et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 2010b; 20: 295-301.
5. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991; 49: 54-67. (Pubitemid 21891653)
6. Beroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 2007; 28: 196-202. (Pubitemid 46233317)
7. Bhasin N, Law R, Liao G, Safer D, Ellmer J, Discher BM, et al. Molecular extensibility of mini-dystrophins and a dystrophin rod construct. J Mol Biol 2005; 352: 795-806. (Pubitemid 41268659)
8. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003; 13: 166-72. (Pubitemid 36140013)
9. Bushby KM, Gardner-Medwin D, Nicholson LV, Johnson MA, Haggerty ID, Cleghorn NJ, et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 1993; 240: 105-12. (Pubitemid 23073201)
10. Cacchiarelli D, Incitti T, Martone J, Cesana M, Cazzella V, Santini T, et al. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep 2011; 12: 136-41.
11. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.
12. Comi GP, Prelle A, Bresolin N, Moggio M, Bardoni A, Gallanti A, et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 1994; 117 (Pt 1): 1-14. (Pubitemid 24103380)
13. Ervasti JM. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta 2007; 1772: 108-17. (Pubitemid 46123911)
14. Ferreiro V, Giliberto F, Muniz GM, Francipane L, Marzese DM, Mampel A, et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 2009; 39: 239-43.
15. Finanger Hedderick EL, Simmers JL, Soleimani A, Andres-Mateos E, Marx R, Files DC, et al. Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders. Neurology 2011; 76: 960-7.
16. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-22.
17. Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, den Dunnen JT, Verbist BM, Bakker E, et al. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 2010; 20: 251-4.
18. Henderson DM, Belanto JJ, Li B, Heun-Johnson H, Ervasti JM. Internal deletion compromises the stability of dystrophin. Hum Mol Genet 2011; 20: 2955-63.
19. Kaspar RW, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. Circ Cardiovasc Genet 2009; 2: 544-51.
20. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918-28.
21. Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992; 50: 950-9.
22. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008; 456: 511-5. (Pubitemid 352759004)
23. Krieger CC, Bhasin N, Tewari M, Brown AE, Safer D, Sweeney HL, et al. Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics. Cytoskeleton (Hoboken) 2010; 67: 796-807.
24. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009; 119: 624-35.
25. Le Rumeur E, Winder SJ, Hubert JF. Dystrophin: more than just the sum of its parts. Biochim Biophys Acta 2010; 1804: 1713-22.
26. Lesca G, Testard H, Streichenberger N, Pelissier JF, Lestra C, Burel E, et al. [Family study allows more optimistic prognosis and genetic counselling in a child with a deletion of exons 50-51 of the dystrophin gene]. Arch Pediatr 2007; 14: 262-5. (Pubitemid 46357613)
27. Lu QL, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P, et al. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 2000; 148: 985-96.
28. Matsumura K, Tome FM, Collin H, Leturcq F, Jeanpierre M, Kaplan JC, et al. Expression of dystrophin-associated proteins in dystrophinpositive muscle fibers (revertants) in Duchenne muscular dystrophy. Neuromuscul Disord 1994; 4: 115-20.
29. Melacini P, Fanin M, Danieli GA, Fasoli G, Villanova C, Angelini C, et al. Cardiac involvement in Becker muscular dystrophy. J Am Coll Cardiol 1993; 22: 1927-34. (Pubitemid 23359655)
30. Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996; 94: 3168-75. (Pubitemid 26427483)
31. Melis MA, Cau M, Muntoni F, Mateddu A, Galanello R, Boccone L, et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol 1998; 2: 255-61. (Pubitemid 28553033)
32. Miyagoe-Suzuki Y, Takeda SI. Association of neuronal nitric oxide synthase (nNOS) with alpha1-syntrophin at the sarcolemma. Microsc Res Tech 2001; 55: 164-70. (Pubitemid 33029629)
33. Miyazaki D, Yoshida K, Fukushima K, Nakamura A, Suzuki K, Sato T, et al. Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene. J Hum Genet 2009; 54: 127-30.
34. Morandi L, Mora M, Confalonieri V, Barresi R, Di Blasi C, Brugnoni R, et al. Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype. J Neurol Sci 1995; 132: 146-55.
35. Morrone A, Zammarchi E, Scacheri PC, Donati MA, Hoop RC, Servidei S, et al. Asymptomatic dystrophinopathy. Am J Med Genet 1997; 69: 261-7. (Pubitemid 27154667)
36. Muntoni F, Di Lenarda A, Porcu M, Sinagra G, Mateddu A, Marrosu G, et al. Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy. Heart 1997; 78: 608-12. (Pubitemid 28034215)
37. Muntoni F, Mateddu A, Cianchetti C, Marrosu MG, Clerk A, Cau M, et al. Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy. J Neurol Neurosurg Psychiatry 1993; 56: 26-31. (Pubitemid 23062975)
38. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2: 731-40. (Pubitemid 37443515)
39. Nakamura A, Yoshida K, Fukushima K, Ueda H, Urasawa N, Koyama J, et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 2008; 15: 757-63.
40. Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 2007; 17: 913-8. (Pubitemid 350137731)
41. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients. J Med Genet 1993; 30: 737-44. (Pubitemid 23270816)
42. Ozawa E. Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 798-821.
43. Pegoraro E, Hoffman EP, Piva L, Gavassini BF, Cagnin S, Ermani M, et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76: 219-26.
44. Pietri-Rouxel F, Gentil C, Vassilopoulos S, Baas D, Mouisel E, Ferry A, et al. DHPR alpha1S subunit controls skeletal muscle mass and morphogenesis. EMBO J 2010; 29: 643-54.
45. Saengpattrachai M, Ray PN, Hawkins CE, Berzen A, Banwell BL. Grandpa and I have dystrophinopathy?: approach to asymptomatic hyperCKemia. Pediatr Neurol 2006; 35: 145-9. (Pubitemid 44093977)
46. Sanchez-Arjona MB, Rodriguez-Uranga JJ, Giles-Lima M, Fernandez-Garcia R, Chinchon-Lara I, Antinolo G, et al. Spanish family with myalgia and cramps syndrome. J Neurol Neurosurg Psychiatry 2005; 76: 286-9. (Pubitemid 40143729)
47. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000; 97: 13818-23.
48. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci USA 1998; 95: 15090-5. (Pubitemid 29003761)
49. Torelli S, Brown SC, Jimenez-Mallebrera C, Feng L, Muntoni F, Sewry CA. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 2004; 30: 540-5. (Pubitemid 39423041)
50. Tselikas L, Rodrigues E, Jammal M, Tiev K, Chayet C, Josselin-Mahr L, et al. [Late onset Becker muscular dystrophy. A case report and literature review.]. Rev Med Interne 2010; 32: 181-6.
51. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357: 2677-86.
52. van Vliet L, de Winter CL, van Deutekom JC, van Ommen GJ, Aartsma-Rus A. Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet 2008; 9: 105.
53. Wood MJ, Gait MJ, Yin H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain 2010; 133 (Pt 4): 957-72.
54. Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP. A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 2009; 66: 32-8.